Slide 1: Getinge to acquire Applikon Biotechnology B.V.
Getinge to acquire Applikon Biotechnology B.V. Mattias Perjos, President & CEO Lars Sandström, CFO Conference Call, December 19, 2019
Slide 2: Getinge to acquire Applikon Biotechnology B.V. – strengthening the offer to biopharma customers
Getinge to acquire Applikon Biotechnology B.V. – strengthening the offer to biopharma customers Leading company World leader in solutions to in advanced bioreactor systems for prevent contamination bioprocessing in pharmaceutical production and to and cell and (Life Science Business Area) ensure int
Slide 3: Comprehensive offer and relevant core competencies
Comprehensive offer and relevant core competencies – a long-term partner to biopharma companies Flexibility: able to configure individual solutions Portfolio overview Efficiency: Scalability: + + + + newly launched software enabling Core wide portfolio from detection and seamless Competencies develo
Slide 4: Applikon Biotechnology is present in four out of five segments
Applikon Biotechnology is present in 3 out of 4 segments – and have a strong R&D pipeline to drive future growth Single Multiple use use bioreactors Large Strong R&D pipeline Launched ground- Attractive breaking recurring single use revenue small reactor based on system in Unique 2019 ability to up-
Slide 5: A perfect fit with Getinge Life Science
A perfect fit with Getinge Life Science – a true win-win for both organizations Portfolio fit Geographical fit Technological fit A leader in early phases of the value Bio-reactors in stainless steel are chain whereas Getinge Life Science is Direct sales in North and South America, pressure vessels w
Slide 6: Value creation from a shareholder perspective
Value creation from a shareholder perspective – expecting long-term margin expansion Net sales growth increase • Adding approx. SEK 450 M in net sales and positive growth outlook • Strengthened portfolio for diversified growth in Biopharma segment Purchase price, MEUR 60 • Significant potential from
Slide 7: Key take-aways
Key take-aways Offer, fit and growth potential for Life Science Financial consequences • Strengthening the offer towards biopharma customers • ~450 MSEK in added net sales • Perfect fit from a portfolio, geographical, customer and • Margin expansion expected in coming years for Life technological pe
Slide 8: Q&A
Q&A Getinge December 19, 2019 Page 8
Slide 9: Thank you
Thank you Getinge December 19, 2019 Page 9
Slide 10: Forward looking information
Forward looking information This document contains forward-looking information based on the current expectations of the Getinge’s management. Although management deems that the expectations presented by such forward-looking information are reasonable, no guarantee can be given that these expectation
Slide 11: Getinge
Se A GETINGE PASSION FOR LIFE